ReviewFrontiers in nutrition2024
Current approach to the diagnosis of sarcopenia in cardiovascular diseases.
Review in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of exercise interventions on inflammatory biomarker levels in older adults with frailty and/or sarcopenia: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Musculoskeletal degeneration and cardiovascular aging: a narrative review of shared mechanobiological pathways.Molecular biology reports · 2026Review
- Sarcopenia in atrial fibrillation: a prospective study.Turkish journal of medical sciences · 2026Article
- Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD-A Narrative Review.International journal of molecular sciences · 2025Review
- Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach.International journal of molecular sciences · 2025Review
- Global trends in sarcopenia and cancer over the past 10 years: a bibliometric analysis.Discover oncology · 2025Article
- Muscle or Heart? Functional Impact of Sarcopenia and Heart Failure in Geriatric Inpatients.Journal of clinical medicine · 2025Article
- Impact of muscle strength decline and exercise intervention on multimorbidity of chronic diseases in older adults.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Sarcopenia and Cardiogeriatrics: The Links Between Skeletal Muscle Decline and Cardiovascular Aging.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle wasting syndrome, also known as sarcopenia, is an age-related geriatric condition characterized by a gradual loss of muscle mass, strength, and function. Sarcopenia can be classified into primary and secondary types. Primary sarcopenia is primarily associated with aging, while secondary sarcopenia is caused by systemic diseases such as cancer, diabetes, liver cirrhosis, musculoskeletal disorders, and disuse changes. In recent years, increasing evidence suggests that cardiovascular diseases can promote the occurrence of sarcopenia through various pathophysiological mechanisms. Additionally, sarcopenia increases the risk of adverse outcomes in patients with cardiovascular disease such as rehospitalization and mortality. Therefore, screening and diagnosing sarcopenia are particularly important for patients with cardiovascular diseases. This article provides a brief overview of the research progress on diagnostic methods for sarcopenia in patients with cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.